FTSE AIM All-Share Industrial Technology Outlook for September 2026
Industrial-technology companies are geared to the health of manufacturing, science and infrastructure spending. Capital-goods demand, research budgets, factory automation and construction activity all feed through to their order books, and the cycle has been uneven in 2026: some end-markets, such as US scientific research and offshore wind, have softened, while others, including automation and certain industrial niches, have held up better. Order intake and order-book trends are therefore watched closely, because they signal future Revenue before it appears in the income statement.
Many of these businesses grow through a combination of organic development and Acquisition — the buy-and-build model is common in the sector, allowing companies to consolidate fragmented markets and add capability. Execution on acquisitions, and the integration and synergy delivery that follow, are important to their performance, as is the discipline of balance-sheet management given the Debt sometimes taken on to fund deals.
External factors shape the group. Currency movements affect companies with significant overseas revenue; input-cost Inflation bears on margins; and end-market cycles — in research funding, industrial production or consumer-goods packaging — drive demand. The three companies here are all profitable and cash-generative, but face different near-term conditions: Judges Scientific is managing softer scientific-instrument demand, Flowtech Fluidpower is growing through acquisition, and Mpac Group is reshaping its portfolio while warning on near-term profit. A note on constituents: this article substitutes Judges Scientific for a company named in the original sector brief that has transferred to the Main Market of the London Stock Exchange and is therefore no longer eligible for the FTSE AIM All-Share; the rationale appears in the accompanying completion record.
Judges Scientific plc (LSE:JDG)
Judges Scientific is a group that acquires and develops businesses making scientific instruments — precision equipment used in research, testing and industry across fields from materials science to oceanography. Its long-running buy-and-build model has made it one of AIM's most admired compounders, combining organic growth with disciplined acquisitions and strong cash generation. Judges is included here as a substitute for a company named in the original sector brief that has left AIM for the Main Market; as an AIM-quoted, profitable industrial-technology group, it is a representative constituent of the theme.
The company's strategy is to buy high-quality, niche instrument makers at sensible prices, support their development, and use the resulting Cash Flow to fund further acquisitions and a growing Dividend — a model that has delivered strong long-term returns, albeit with sensitivity to research-funding and industrial cycles.
Latest results and softer demand
For the year ended 31 December 2025, Judges Scientific reported revenue up 9.1% to £145.8 million and adjusted operating profit broadly flat at £28.0 million, with adjusted Basic Earnings Per Share of 275.3p, down 2.9%. Cash generated from operations was strong at £33.0 million, representing 118% cash conversion, and adjusted net debt improved to £42.6 million from £51.7 million. The board proposed a total dividend of 115p per share, a 10% increase covered 2.4 times by adjusted earnings — evidence of continued confidence despite a tougher trading environment.
The results reflected genuine headwinds. Organic order intake declined 6% on a like-for-like basis, and the order book contracted to 15.7 weeks from 18.7 weeks, reflecting reduced Demand particularly in the United States, where federal research-funding uncertainty weighed on orders, alongside softness in offshore-wind markets. Much of the year's organic revenue growth was driven by a Geotek coring expedition in the first quarter, with underlying like-for-like growth of only around 2%. Looking ahead, management guided to 2026 adjusted earnings per share of 200–250p, assuming no coring expedition until early 2027 and continued US trading challenges, and noted that year-to-date order intake through mid-2026 was running 17% below the prior-year comparative.
Catalysts and risks
Identifiable catalysts include a recovery in order intake, particularly in the US as research-funding uncertainty resolves; further earnings-accretive acquisitions funded by strong cash generation; the timing of the next Geotek coring expedition; and continued dividend growth. The buy-and-build model provides a route to growth even in a soft organic environment.
The risks include the cyclicality of scientific-instrument demand and specific exposure to US research funding and offshore wind; the reliance on acquisitions for growth, which carries execution and valuation risk; currency translation on overseas revenue; and the near-term earnings pressure implied by the guided 2026 range and weaker order intake. As at 14 September 2026 the shares traded at about 3,950p, capitalising the company at roughly £263 million on London market data — a valuation reflecting its quality and track record, but sensitive to the demand recovery and acquisition delivery.
Flowtech Fluidpower plc (LSE:FLO)
Flowtech Fluidpower is the UK's leading specialist distributor of fluid-power products — hydraulic and pneumatic components used across industry, from Manufacturing and construction equipment to infrastructure. It supplies a broad catalogue of parts to a fragmented base of industrial customers, and has been growing through a combination of acquisitions and the development of its distribution and E-commerce capabilities. It is a profitable, cash-generative distributor exposed to the general health of UK and European industrial activity.
The company's strategy is to consolidate the fragmented fluid-power distribution market through acquisition, expand its digital and e-commerce channels, and improve margins through scale and operational efficiency.
Latest results and acquisitions
For the first half of 2026, the six months to 30 June 2026, Flowtech reported revenue up 23.8% to £70.4 million, with like-for-like sales rising a healthy 13.3%, indicating organic growth well beyond the contribution from acquisitions. Underlying EBITDA was £4.5 million and profit before tax was £0.7 million, marking a return to profit, though gross Margin declined to 37.0% and cash flow was somewhat weaker. Net debt reduced to £16.4 million, with £8.6 million of available headroom under facilities, helped by cost controls and lower working capital, and the order book stood more than 20% higher than at the start of the year.
Growth came across all three of its regions — Great Britain, Ireland and Benelux — and the company continued integrating its recent acquisitions of Thorite, Q Plus and Helipebs while rolling out its UK e-commerce platform, with planned expansion to Ireland and Benelux. Management expected profitability and cash generation to increase in the second half, with gross-margin improvement anticipated, supported by engineering projects and measures to offset inflation. The picture is one of strong revenue growth and a rising order book, tempered by margin pressure that the company aims to address in the second half.
Catalysts and risks
Identifiable catalysts include the anticipated second-half improvement in profitability and margins, continued integration and synergy delivery from recent acquisitions, growth in the e-commerce platform, delivery of the two major bridge contracts referenced, and any further acquisitions.
The risks include exposure to UK and European industrial activity, which can be cyclical; the margin pressure evident in the first half; the execution and integration risk of its acquisition strategy; the debt used to fund growth; and competition in fluid-power distribution. As at 14 September 2026 the shares traded at about 63.5p, capitalising the company at roughly £51 million on London market data — a valuation reflecting its revenue growth and order book, but dependent on the second-half margin recovery and continued industrial demand.
Mpac Group plc (LSE:MPAC)
Mpac Group is a global packaging and automation solutions company, designing and manufacturing high-speed packaging machinery and automation systems for sectors including healthcare, food and beverage, and consumer goods. It combines original-equipment machinery sales with a service and aftermarket business, and has grown through acquisition. The company has been reshaping its portfolio to focus on scalable, full-line packaging machinery, and its performance is heavily influenced by order intake and the timing of large capital-equipment projects.
Mpac's strategy is to concentrate on scalable, repeatable packaging-machinery solutions and its recurring service business, divesting activities that do not fit that model, while managing the lumpiness inherent in capital-equipment sales.
Portfolio reshaping and near-term profit warning
In a June 2026 trading update, Mpac announced the sale of its Lambert Business — a maker of bespoke medical and consumer-healthcare assembly systems, including the SIGA Vision operation acquired in 2024 — to Italian automation group Mech.i.Tronic for £16 million upfront plus a potential £4 million earn-out, subject to National Security and Investment Act clearance expected in the third quarter of 2026. Management explained that Lambert, with its focus on highly customised, bespoke projects, did not fit the group's strategy of scalable, full-line packaging machinery, and the disposal will significantly reduce net debt, which stood at £47.9 million at the end of 2025.
The update was not without disappointment: the company reported that first-half margins would be below the prior year and that full-year 2026 Underlying Profit before tax would be substantially below current market expectations — a clear near-term profit warning. On a more positive note, the order book improved to £98.8 million as of May 2026, up from £90.0 million at the year-end, providing a base for future revenue. The combination of a strategically sensible disposal and a rising order book, set against a near-term profit warning, defines Mpac's current position.
Catalysts and risks
Identifiable catalysts include completion of the Lambert disposal and the associated reduction in net debt, conversion of the improved order book into revenue, delivery of the refocused full-line packaging strategy, and any recovery in underlying profitability from the level flagged in the profit warning.
The risks are significant. The near-term profit warning highlights the sensitivity of Mpac's earnings to margins and project timing; the business carries meaningful net debt, which the disposal is intended to reduce; capital-equipment demand can be lumpy and cyclical; and the reshaping of the portfolio carries execution risk. As at 14 September 2026 the shares traded at about 355p, capitalising the company at roughly £107 million on London market data — a valuation that will reflect both the improved order book and the near-term earnings pressure.
What Could Drive the Sector Through the Rest of 2026?
End-market demand and order intake will remain the key drivers. Judges Scientific's exposure to US research funding and offshore wind, Flowtech's to UK and European industrial activity, and Mpac's to capital-equipment cycles each illustrate how sector-specific conditions shape order books. A recovery in research funding or industrial production would support order intake, while continued softness would weigh on it, and the order-book trends reported by each company are the clearest near-term signal.
Acquisitions and Portfolio Management are central to the sector's growth. Judges' buy-and-build model, Flowtech's consolidation of fluid-power distribution, and Mpac's disposal of Lambert all reflect active portfolio strategies. Execution on acquisitions and disposals — including integration, synergy delivery and debt management — will influence performance, and the discipline with which each company allocates Capital matters to returns.
Margins and cash generation differentiate the businesses. Flowtech's first-half margin pressure and Mpac's profit warning highlight the importance of converting revenue into profit and cash, while Judges' strong cash conversion underpins its dividend and acquisition capacity. In a mixed demand environment, the market is likely to reward reliable margins and cash generation.
Currency and cost trends form the backdrop. All three companies have some overseas exposure, and sterling's level affects reported results; input-cost inflation bears on margins across the sector. Developments in these areas, alongside the direction of the industrial and research cycles, will shape performance through the remainder of 2026.
Potential Catalysts to Watch
For Judges Scientific, the identifiable catalysts are a recovery in order intake, particularly in the US; further earnings-accretive acquisitions; the timing of the next Geotek coring expedition; and continued dividend growth against the guided 2026 earnings range.
For Flowtech Fluidpower, watch for the anticipated second-half improvement in profitability and margins, continued integration of the Thorite, Q Plus and Helipebs acquisitions, growth in the e-commerce platform, and delivery of the major bridge contracts.
For Mpac Group, the key events are completion of the Lambert disposal and the associated debt reduction, conversion of the improved order book into revenue, and any recovery in underlying profitability from the warned-on level. As always, these are potential rather than assured outcomes, and their effects could be positive or negative.
Key Risks Investors Should Consider
Demand and cyclicality risk affects all three. Judges Scientific faces softer scientific-instrument demand and specific US research-funding exposure; Flowtech is geared to industrial activity; and Mpac's near-term profit warning underlines the sensitivity of capital-equipment earnings to margins and project timing. A weaker industrial or research environment would pressure order intake and revenue across the group.
Execution and balance-sheet considerations apply. Judges and Flowtech rely on acquisitions for growth, with the associated integration and valuation risks, and both carry net debt; Mpac carries meaningful net debt that its disposal is intended to reduce, and its portfolio reshaping carries execution risk. Margin pressure, as seen at Flowtech and Mpac, can erode the benefit of revenue growth.
Currency and competition are further considerations. Overseas revenue exposes all three to exchange-rate movements, and each faces competition in its niche. While these are profitable, established businesses rather than speculative junior-market names, they are not risk-free: the near-term profit warning at Mpac in particular illustrates that industrial-technology earnings can disappoint. Readers should weigh these company-specific risks against the sector's long-term drivers.
Conclusion
Judges Scientific, Flowtech Fluidpower and Mpac Group represent the industrial-technology end of AIM — profitable, cash-generative businesses whose fortunes track order books, acquisitions and end-market cycles. Judges is the high-quality instrument compounder, maintaining its dividend and acquisition capacity while managing softer research-driven demand and a lower order book. Flowtech is the fluid-power distributor, growing strongly through acquisition and Organic Sales but working to restore margins in the second half. Mpac is the packaging-machinery maker, reshaping its portfolio through the Lambert disposal and building its order book, but having warned on near-term profit.
Order intake, acquisitions and disposals, and margin delivery will drive the sector through the rest of 2026. The companies differ in their conditions — softer demand at Judges, margin pressure at Flowtech, and a profit warning at Mpac — but share the cash generation and market positions that distinguish quality industrial businesses. Market Participants are likely to monitor Judges' order recovery and acquisitions, Flowtech's second-half margins, and Mpac's Lambert completion and order-book conversion. Each carries its own risks, which readers should weigh for themselves. No recommendation to buy, sell or hold is made or implied.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...